Cite
HARVARD Citation
Schjesvold, F. et al. (2022). Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet. 9 (2), pp. e98-e110. [Online].